Department of Internal Medicine and Infectious Diseases, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt.
Central Laboratory for Evaluation of Veterinary Biologics (CLEVB), Cairo, Egypt.
Int J Nanomedicine. 2020 Sep 23;15:6993-7011. doi: 10.2147/IJN.S270204. eCollection 2020.
The main objective of this study is to investigate the antibacterial activity of silver nanoparticles (AgNPs) against multidrug-resistant isolates recovered from diarrheic sheep and goats.
This study used chemical reduction synthesis of AgNPs to evaluate their antimicrobial effects by estimation of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for each isolate using the microplate dilution method and tetrazolium salt reduction test to detect the viability percentage. In vivo treatment efficacy was assessed in mice by determining the viable count of Enteritidis recovered from feces and by hematologic, biochemical and histopathologic examinations to confirm that use of AgNPs has no toxic or pathologic effects and to evaluate its ability in tissue regeneration following treatment.
All recovered strains were identified as MDR with a prevalence of 4% and 3.6% in sheep and goats, respectively. The results of TEM, DLS, Zeta potential, and FTIR revealed typical characteristics of the synthesized AgNPs. Silver nanoparticles showed antibacterial activity against all recovered strains with MIC of ≤0.02-0.313 μg/mL (mean average 0.085±0.126 μg/mL) and MBC of 0.078-1.250 μg/mL (average 0.508±0.315 μg/mL). In vivo efficacy of AgNPs was observed by a reduction in the number of viable . Enteritidis recovered from feces in an . Enteritidis infected mouse model, with complete shedding stopping between treatment days 4 and 6. Hematologic, serum biochemical, and histopathologic analyses proved the ability of AgNPs to suppress inflammatory reaction caused by . Enteritidis infection.
The study proved the effective ability of AgNPs to fight MDR spp. in vitro and in vivo without adverse effects.
本研究的主要目的是研究银纳米粒子(AgNPs)对从腹泻绵羊和山羊中分离出的多药耐药株的抗菌活性。
本研究采用化学还原法合成 AgNPs,通过微量稀释法测定最小抑菌浓度(MIC)和最小杀菌浓度(MBC),以及四唑盐还原试验检测活菌百分比,评估其抗菌效果。通过测定从粪便中回收的肠炎沙门氏菌的活菌数,并通过血液学、生化和组织病理学检查,评估 AgNPs 的体内治疗效果,以确认其使用无毒性或病理作用,并评估其在治疗后的组织再生能力。
所有回收的菌株均被鉴定为 MDR,绵羊和山羊的检出率分别为 4%和 3.6%。TEM、DLS、Zeta 电位和 FTIR 的结果显示合成的 AgNPs 具有典型的特征。银纳米粒子对所有回收的菌株均表现出抗菌活性,MIC 为≤0.02-0.313μg/mL(平均 0.085±0.126μg/mL),MBC 为 0.078-1.250μg/mL(平均 0.508±0.315μg/mL)。AgNPs 的体内疗效通过减少肠炎沙门氏菌感染小鼠模型中粪便中活菌的数量来观察,在治疗第 4-6 天完全停止脱落。血液学、血清生化和组织病理学分析证明了 AgNPs 抑制肠炎沙门氏菌感染引起的炎症反应的能力。
本研究证明了 AgNPs 在体外和体内有效对抗 MDR 株,且无不良反应。